Quince Therapeutics, Inc. (QNCX)
NASDAQ: QNCX · Real-Time Price · USD
1.230
-0.060 (-4.65%)
At close: Apr 28, 2026, 4:00 PM EDT
1.220
-0.010 (-0.80%)
After-hours: Apr 28, 2026, 7:58 PM EDT
Quince Therapeutics Employees
Quince Therapeutics had 38 employees as of December 31, 2025. The number of employees increased by 2 or 5.56% compared to the previous year.
Employees
38
Change (1Y)
2
Growth (1Y)
5.56%
Revenue / Employee
n/a
Profits / Employee
-$2,209,974
Market Cap
20.05M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Passage Bio | 24 |
| Curis | 24 |
| OSR Holdings | 22 |
| NewcelX | 15 |
| Lipocine | 14 |
| Serina Therapeutics | 13 |
| Cocrystal Pharma | 10 |
| VYNE Therapeutics | 10 |
QNCX News
- 4 weeks ago - Quince Therapeutics Settles Approximately $16.4 Million of Debt - Business Wire
- 2 months ago - Quince Therapeutics Stock Plunges As Filing Shows Reverse Merger Plans, Bankruptcy Risks - Benzinga
- 2 months ago - Quince Therapeutics Stock Explodes 300% On Strategic Review - Benzinga
- 2 months ago - Quince Therapeutics Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Alternatives - Business Wire
- 3 months ago - Quince Therapeutics Announces Topline Results from Pivotal Phase 3 NEAT Clinical Trial of eDSP in Ataxia-Telangiectasia - Business Wire
- 3 months ago - Quince Therapeutics Presents Safety Data from Long-Term eDSP Treatment in Children with Ataxia-Telangiectasia at British Paediatric Neurology Association Annual Meeting - Business Wire
- 4 months ago - Quince Therapeutics Announces Last Patient Last Visit in Phase 3 NEAT Clinical Trial in Patients with Ataxia-Telangiectasia - Business Wire
- 4 months ago - Quince Therapeutics Announces Publication of Use of eDSP in Early-Stage Clinical Studies in Pulmonary and Inflammatory Bowel Disorders - Business Wire